Syros Pharmaceuticals Inc (NASDAQ:SYRS) Could Improve Your Long Portfolio After Less Shorts Reported

June 11, 2018 - By Richard Conner

The stock of Syros Pharmaceuticals Inc (NASDAQ:SYRS) registered a decrease of 12.53% in short interest. SYRS’s total short interest was 1.36 million shares in June as published by FINRA. Its down 12.53% from 1.56 million shares, reported previously. With 129,000 shares average volume, it will take short sellers 11 days to cover their SYRS’s short positions. The short interest to Syros Pharmaceuticals Inc’s float is 8.98%.

The stock decreased 0.28% or $0.035 during the last trading session, reaching $12.465. About 109,596 shares traded. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has declined 14.15% since June 11, 2017 and is downtrending. It has underperformed by 26.72% the S&P500.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $406.09 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

More news for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) were recently published by: Businesswire.com, which released: “Syros to Present at Upcoming Investor Conferences” on May 30, 2018. Nasdaq.com‘s article titled: “Report: Exploring Fundamental Drivers Behind Syros Pharmaceuticals, J & J Snack Foods, Wright Medical Group NV …” and published on May 21, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.